ReviewCancer informatics2015
What Tumor Dynamics Modeling Can Teach us About Exploiting the Stem-Cell View for Better Cancer Treatment.
Review in Cancer informatics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The cancer stem cell hypothesis is that in human solid cancers, only a small proportion of the cells, the cancer stem cells (CSCs), are self-renewing; the vast majority of the cancer cells are unable to sustain tumor growth indefinitely on their own. In recent years, discoveries have led to the concentration, if not isolation, of putative CSCs. The evidence has mounted that CSCs do exist and are important. This knowledge may promote better understanding of treatment resistance, create opportunities to test agents against CSCs, and open up promise for a fresh approach to cancer treatment. The first clinical trials of new anti-CSC agents are completed, and many others follow. Excitement is mounting that this knowledge will lead to major improvements, even breakthroughs, in treating cancer. However, exploitation of this phenomenon may be more successful if informed by insights into the population dynamics of tumor development. We revive some ideas in tumor dynamics modeling to extract some guidance in designing anti-CSC treatment regimens and the clinical trials that test them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.